Iridex to Present at the 34th Annual Roth Conference
Iridex Corporation (NASDAQ: IRIX) announced its participation in the 34th Annual Roth Conference, scheduled for March 15, 2022, at 10:00 a.m. PT / 1:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iridex Corporation (NASDAQ: IRIX) announced its participation in the 34th Annual Roth Conference, scheduled for March 15, 2022, at 10:00 a.m. PT / 1:00 p.m. ET. The company specializes in innovative ophthalmic laser-based medical products for treating glaucoma and retinal diseases. A live and archived webcast of the presentation will be accessible on the company's website. Iridex is recognized for its MicroPulse® technology, which offers effective treatments for various sight-threatening eye conditions, with products available in over 100 countries.
Details
News Market Reaction – IRIX
The recorded move for IRIX in the trading session of this news was +0.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming 34th Annual Roth Conference.
Management is scheduled to present on Tuesday, March 15, 2022 at 10:00 a.m. PT / 1:00 p.m. ET. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com.
About Iridex
Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.
Investor Relations Contact:
Leigh Salvo
(415) 937-5404
investors@iridex.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.